Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Healios KKTSE:4593 +3.75%51 Market Cap is 円37,395.53 Mil as of Aug. 25, 2026. GuruFocus rates TSE:4593 with a GF Score™ of 51/100 and a GF Value™ of 円43.61 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,422 Biotechnology companies, Healios KK ranks better than 58.23% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Healios KK's share price for the quarter that ended in Jun. 2026 was 円253. Healios KK's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 135.00 Mil. Therefore, Healios KK's market cap for the quarter that ended in Jun. 2026 was 円34,155.51 Mil.
Healios KK's quarterly market cap
increased
from Dec. 2025 (円31,709.20 Mil) to Mar. 2026 (円50,625.75 Mil) but then
declined
from Mar. 2026 (円50,625.75 Mil) to Jun. 2026 (円34,155.51 Mil).
Healios KK's annual market cap
increased
from Dec. 2023 (円12,299.60 Mil) to Dec. 2024 (円15,968.76 Mil) and
increased
from Dec. 2024 (円15,968.76 Mil) to Dec. 2025 (円31,709.20 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Healios KK's Enterprise Value for Today is 円29,145.53 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Healios KK Market Cap Related Terms
Healios KK Market Cap Historical Data
* Premium members only.
The historical data trend for Healios KK's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4593 vs VRTX, REGN, RVMD: Market Cap Comparison
For the Biotechnology subindustry, Healios KK's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healios KK Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Healios KK's Market Cap distribution charts can be found below:
* The bar in red indicates where Healios KK's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Healios KK's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Healios KK (TSE:4593) has a Market Cap of 円37,395.53 Mil as of Aug. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Healios KK and its competitors. According to the industry distribution chart, Healios KK ranks #594 out of 1422 companies in the Biotechnology industry, placing it in the top 41.8%.
Is Healios KK's Market Cap too high?
Healios KK's current Market Cap is 円37,395.53 Mil. Based on the distribution chart, Healios KK ranks #594 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Healios KK has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Healios KK's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Healios KK ranks #594 out of 1422 companies for Market Cap. This puts Healios KK in the upper half of its industry. The industry median Market Cap is 121.73. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 121.73, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Healios KK and its competitors. For the Biotechnology industry, the median Market Cap is 121.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Healios KK's current Market Cap is 円37,395.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healios KK stock overvalued right now?
Based on GuruFocus' analysis, Healios KK (TSE:4593) is currently considered Significantly Overvalued. The stock's GF Value™ is 円43.61, compared to a current price of 円277.00 — trading 535.2% above its estimated fair value. The current Market Cap is 円37,395.53 Mil. Healios KK's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Healios KK (TSE:4593), the current Market Cap is 円37,395.53 Mil as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healios KK (TSE:4593) Overvalued in 2026?
Based on GuruFocus' analysis, Healios KK stock appears to be overvalued.
The current stock price of 円277.00 is trading 535.2% above its estimated GF Value™ of 円43.61.
GuruFocus considers Healios KK to be Significantly Overvalued.
Key valuation signals for TSE:4593:
Market Cap: 円37,395.53 Mil
GF Value™: 円43.61 vs. price of 円277.00 (535.2% above fair value)
No single metric tells the full story. See the TSE:4593 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome.
51GF Score
Get the complete analysis for TSE:4593
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4593 has been successfully added to your 
